NDA 020988 · Wyeth Pharms
Protonix Iv
Pantoprazole Sodium · Intravenous
Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Mar 22, 2001
Approved uses
5
Original approval plus efficacy supplements
Registered trials
231
49 Phase 3, 17 recruiting
FAERS reports
150,017
116,373 serious, 16,700 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2026.
PROTONIX I.V. is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Limitations of Use The safety and effectiveness of PROTONIX I.V. for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients. PROTONIX I.V. is a proton pump inhibitor (PPI) indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older. ( 1 ) • pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. ( 1 ) Limitations of Use The safety and effectiveness of PROTONIX I.V. for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients. ( 1 )
Mechanism: Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H + , K + )-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H + , K + )-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2024 Supplement 70 · Efficacy LabelLetter
- Dec 6, 2004 Original approval · Supplement
- Dec 6, 2004 Supplement 27 · Efficacy LabelLetter
- Oct 19, 2001 Supplement 3 · Efficacy · priority review LabelLetter
- Mar 22, 2001 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDALetter
1 products under this application
- PROTONIX IV · PANTOPRAZOLE SODIUM EQ 40MG BASE/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Pantoprazole" as an intervention, any sponsor and status, largest first.
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01776424 · 27,395 participants · Start Feb 28, 2013 · Primary completion Jul 21, 2017
Drug: Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939) and 5 more · For: Prevention & Control
Sites: Birmingham, Alabama; Mobile, Alabama; Anaheim, California · 565 sites in all
- Re-EValuating the Inhibition of Stress Erosions (REVISE) TrialPivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT03374800 · 4,800 participants · Start Jul 9, 2018 · Primary completion Oct 31, 2023
Drug: Placebo (0.9% saline); Pantoprazole · For: Gastrointestinal Hemorrhage (Clinically Important, Upper)
Sites: Omaha, Nebraska; Bankstown, Australia; Blacktown, Australia · 67 sites in all
- Stress Ulcer Prophylaxis in the Intensive Care UnitPivotal-lookingCompleted
Dr. Morten Hylander MøllerAcademic, hospital or other
NCT02467621 · 3,350 participants · Start Jan 2016 · Primary completion Oct 22, 2017
Drug: Pantoprazole · For: Gastrointestinal Bleeding; Stress Ulcers
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 33 sites in all
- Sup-Icu RENal (SIREN)Pivotal-lookingCompleted
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT02718261 · 3,350 participants · Start Feb 2016 · Primary completion Sep 2018
Drug: Pantoprazole; Saline 0.9% (matching placebo) · For: Critical Illness; Acute Kidney Injury; End-stage Renal Disease and 2 more
Sites: Copenhagen, Denmark; Bern, Switzerland
- The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS PatientsPivotal-lookingRecruiting
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT04728516 · 2,600 participants (planned) · Start Apr 12, 2023 · Primary completion Jun 30, 2026
Drug: Vonoprazan-based dual eradication therapy for two weeks; amoxicillin and 1 more · For: Acute Coronary Syndrome; Helicobacter Pylori Infection
Sites: Bozhou, China; Chuzhou, China; Hefei, China · 42 sites in all
- Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00312806 · 2,000 participants (planned) · Start May 2006 · Primary completion Mar 2007
Drug: Pantoprazole · For: Gastroesophageal Reflux Disease (GERD)
Sites: Buenos Aires, Argentina; La Plata, Argentina; Bedford Park SA, Australia · 186 sites in all
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00163306 · 1,200 participants · Start May 2005
Drug: Pantoprazole · For: Gastroesophageal Reflux
Sites: Deutschlandsberg, Austria; Feldbach, Austria; Graz, Austria · 79 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease24,473
- acute kidney injury13,898
- fatigue11,670
- renal failure10,884
- nausea10,752
- pain10,043
- dyspnoea9,795
- diarrhoea9,645
- drug ineffective9,026
- headache8,494
- off label use8,237
- end stage renal disease7,567
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,678 |
| 2005 | 2,531 |
| 2006 | 2,945 |
| 2007 | 2,610 |
| 2008 | 2,828 |
| 2009 | 3,147 |
| 2010 | 3,759 |
| 2011 | 3,563 |
| 2012 | 4,313 |
| 2013 | 3,291 |
| 2014 | 3,732 |
| 2015 | 5,932 |
| 2016 | 5,965 |
| 2017 | 5,590 |
| 2018 | 18,754 |
| 2019 | 16,519 |
| 2020 | 7,908 |
| 2021 | 8,696 |
| 2022 | 10,518 |
| 2023 | 8,441 |
| 2024 | 9,868 |
| 2025 | 10,012 |
| 2026 | 7,415 |
Recalls
1 FDA enforcement reports for this application.
Nov 22, 2016 · Class III · Terminated
Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Protonix IV (Pantoprazole Sodium)
2024 spending
$30K
Beneficiaries
42
346 claims
Per beneficiary
$707
$6.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $41,138 |
| 2021 | $25,675 |
| 2022 | $27,564 |
| 2023 | $24,157 |
| 2024 | $29,677 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.
Cook D, Deane A, Lauzier F, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis.
Choudhury A, Jena A, Jearth V, et al. · Expert Rev Gastroenterol Hepatol 2023 · Meta-Analysis, Systematic Review
- Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.
Zou S, Ouyang M, Cheng Q, et al. · Pharmacotherapy 2024 · Systematic Review, Network Meta-Analysis
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P, Eikelboom JW, Bosch J, et al. · Gastroenterology 2019 · Multicenter Study, Randomized Controlled Trial
- Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.
Krag M, Marker S, Perner A, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
- Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
Zhuang Q, Chen S, Zhou X, et al. · Am J Gastroenterol 2024 · Systematic Review, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.